TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Exercise Self-Efficacy (ESE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment failure-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: grade 3-4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: family centredness of care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Prevalence and distribution of OMA-DO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in morning PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective nasal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective nasal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: later speech attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: later walking attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean keratinized gingival width increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLT yield per donation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual WBC count per unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Global myocardial (123)I‐MIBG washout
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: relapse tendency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with swollen joint PABAK >0.6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of disease remission (28-joint DAS <2.6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of glottic opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Initial virologic suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+ cell decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pVL <3.0 log(10) copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean sensitivity in SLO perimetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerobic endurance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total movement duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: returning movement duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality rate in septic shock patients
Endpoint domain: Mortality/survival
Primary endpoint: BaPWV (brachial-ankle pulse wave velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maternal tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reliability of the screening tool (SIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-h postprandial glucose area under the curve reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: myopic regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective haze grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of phrenic nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WSL remineralization effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cancer-specific survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Prostate cancer risk reduction
Endpoint domain: Mortality/survival
Primary endpoint: AI75 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cross-clamp time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chloride concentrations in neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major response rate (complete response and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin action impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Relative abundance of apoC‐III2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative abundance of apoC‐III1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial overgrowth of E. coli
Endpoint domain: Adverse events/effects
Primary endpoint: mucosal edema and submucosal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidural fentanyl consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increased meniscal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regained lost activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fewer non-protocol reoperations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Heparin dosing requirement to achieve ACT >300s
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic oxidative stress balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Room time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Control of hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BDI score predicting inability to quit smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of mite numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of Der p 1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in histamine PC(20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oral bioavailability of diprafenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative score for symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FE(NO) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AMP PC(20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: final outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of anesthetic agents required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Consumption of fried snacks
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: OMERACT-OARSI responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days needed to transfer from bed to chair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of azygos vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reliability of IIEF‐5 and IIEF‐15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation-related hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Functional capacity (pVO2, 6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (SF-36 subscales)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adjusted mean attitude postscores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Favorable effect on serum triglycerides at 8 and 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognitive control performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of NLRP3 and cathepsin-B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BPRS-C reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: school readiness scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 3-month PSA decline of at least 30%
Endpoint domain: Mortality/survival
Primary endpoint: Number of flu and acute respiratory infection symptomatic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hunger rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of PLP in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of 4-PA in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of PL in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to carbachol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: redistribution of thallium-201
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of vaccination records
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Client counseling effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Health worker motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ASAS20 response rates at week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Cardiac Output (CPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improved health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective anxiety ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: extracerebral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maternal plasma iron concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mRNA levels of transferrin receptor 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ferritin in infant cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Preclinical Survival Time (MPST) for lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: Netupitant area under curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Netupitant C max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic exposure to levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total bone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean non-vital bone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean osteoid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of overall satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discontinuation due to inadequate pain relief
Endpoint domain: Adverse events/effects
Primary endpoint: no nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle-brachial index increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: tolerance of preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: quality of bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: adverse side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of NO, OFR, LPO, MHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of SOD, CAT, Cyt b5‐R
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hepatic artery buffer index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportionate change in BMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportionate change in serum 25-hydroxycholecalciferol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportionate change in serum calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of specific interventions recommended to the GP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stable vision (loss of ≤15 ETDRS letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD response in the dorsomedial prefrontal cortex during performance monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time to complete clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QLF changes consistent with mineral gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACC activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximal voluntary contraction force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H-reflex depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response rates for mania and depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chance of relapse to mania or depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to resolution of vasopressor-dependent hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gain in clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Resolution of osseous defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decreases in abdominal fat area (AFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreases in subcutaneous fat area (SFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreases in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numeric rating pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid medication use at home
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effective analgesia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h analgesic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dystrophin content increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dystrophin immunofluorescence intensity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exon skipping confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion at 90° abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tear fluid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUM score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ki67-positive cells reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-cell subsets reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Death or myocardial infarction by 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Plasma concentrations of unbound ropivacaine and PPX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative pain relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Signs or symptoms of systemic local anesthetic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean number of maternal hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean birth weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent episodes of bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Engagement in treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at individual appointments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to treatment engagement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TKR incidence
Endpoint domain: Mortality/survival
Primary endpoint: Mortality at day 60
Endpoint domain: Mortality/survival
Primary endpoint: Rate of catheter-related bloodstream infections
Endpoint domain: Adverse events/effects
Primary endpoint: Glycosylated hemoglobin (HbA(1c)) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive attitudes towards patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores on assessment checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on management checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BAS-G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-perceived improvement in communication skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: retention of confidence in BBN skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decrease in pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: increased use of salbutamol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: development of severe asthma symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic yield of NTG-HUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of A-HUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous abnormalities identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: benefit of duplex ultrasound in surgical site selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative 3‐year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Good response after salbutamol inhalations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in detection of epileptiform activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in interictal spike rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in spectral power (1-125 Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean calculated total blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients with plasma HIV-1 RNA <400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until eye opening upon request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of high-risk HPV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Seroprevalence of neutralizing antibodies against HPV-16 and HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Naïve status to HPV-16 and HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: iMVCquad-HHD values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of clinical symptoms (NIH-CPSI scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of pro-inflammatory cytokines (TNF-alpha, IL-1beta)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perception scores at 40 mL distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first sensation during capsaicin perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes